KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $57.5 million.

  • Edwards Lifesciences' Capital Expenditures rose 1079.0% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.6 million, marking a year-over-year decrease of 2691.65%. This contributed to the annual value of $252.4 million for FY2024, which is 23.72% down from last year.
  • Edwards Lifesciences' Capital Expenditures amounted to $57.5 million in Q3 2025, which was up 1079.0% from $49.3 million recorded in Q2 2025.
  • Over the past 5 years, Edwards Lifesciences' Capital Expenditures peaked at $106.0 million during Q1 2021, and registered a low of $43.1 million during Q2 2022.
  • In the last 5 years, Edwards Lifesciences' Capital Expenditures had a median value of $60.7 million in 2021 and averaged $65.2 million.
  • Examining YoY changes over the last 5 years, Edwards Lifesciences' Capital Expenditures showed a top increase of 7828.81% in 2024 and a maximum decrease of 4360.14% in 2024.
  • Quarter analysis of 5 years shows Edwards Lifesciences' Capital Expenditures stood at $89.8 million in 2021, then decreased by 23.27% to $68.9 million in 2022, then increased by 28.16% to $88.3 million in 2023, then plummeted by 43.6% to $49.8 million in 2024, then rose by 15.46% to $57.5 million in 2025.
  • Its Capital Expenditures stands at $57.5 million for Q3 2025, versus $49.3 million for Q2 2025 and $56.0 million for Q1 2025.